Oral HRS-7535 Lowered A1c in Trial - Takeaways - MDSpire

Oral HRS-7535 Lowered A1c in Trial

Nonpeptide oral agent requires no fasting administration.

  • By

  • Kathryn Wighton

  • June 5, 2026

  • 9 min

Share

  • 1

    Oral HRS-7535 significantly reduced hemoglobin A1c levels in patients with type 2 diabetes inadequately controlled by metformin.

  • 2

    The trial involved 194 patients and demonstrated that HRS-7535 doses of 60 mg and 90 mg provided similar glycemic control.

  • 3

    Patients receiving HRS-7535 achieved greater reductions in fasting plasma glucose and postprandial glucose compared to placebo.

  • 4

    Gastrointestinal adverse events were common but mostly mild or moderate, with higher rates in the 60-mg dose group.

  • 5

    The study's findings may not directly apply to Western populations due to differences in body mass index and diabetes characteristics.

Original Source(s)

Oral HRS-7535 Lowered A1c in Trial

  • by Kathryn Wighton

  • June 5, 2026

Related Content

COPD Severity Tied to Life Expectancy

A pooled US cohort study estimated years of life lost across airflow obstruction severity, including among adults who never smoked.

Combination Therapy Shows Potential in Psoriasis, Obesity

Researchers assess whether adding tirzepatide to ixekizumab affects skin and weight outcomes in adults with moderate to severe plaque psoriasis.

Side Effects: The Body Keeps Score

Turns out biology tracks more than we thought — from a spit test that reads your all-nighter to a surgical outcome that still shows up in household chores two decades later. Plus: habits aren't built gradually. They snap.